All products are based on MedMira’s patented RVF Technology® and allow a fast, reliable and easy-to-use solution for any settings, specifically for Point-of-Care use. MedMira’s products do not require any other instruments or special settings. Designed to be used from laboratories to home-users
All MedMira’s Products have the following unique features:
- Inexpensive, portable device
- Fast (~3 min) and easy test
DOES NOT REQUIRE
- Specialized equipment, additional reagents and skillful workers
- Sophisticated sample preparation
ALLOWS
- Widespread testing (including asymptomatic patients)
USEFUL IN
- Follow-up screening
- Vaccine development
VYRA™CoV2 detects antigens specific for the nucleocapsid region of SARS-CoV-2, the causative agent of COVID-19, and can determine an active infection in less than 3 minutes. It comes as a fast solution to screen for individuals who are suspected of COVID-19 infection.
Point-of-Use : Intended for the qualitative detection of SARS-CoV-2 antigens in nasal swab specimens. VYRA™COVID-19 is intended for use by healthcare professionals as an aid in identifying individuals with an acute SARS-CoV-2 infection.
Cat. No. 815311009679
Qty. 20 tests per box
Qty. 20 tests per box
Cat. No. 815311009570
Qty. 5 tests per box
This product is not yet approved by the FDA and there cannot be sold at this time in the USA.
VYRA™CoV2Flu is a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2 and Influenza A (Flu A) and Influenza B (Flu B). VYRACoV2Flu is the right tool to screen and differentiate between the viruses causing COVID-19 and Flu A / Flu B.
Point-of-Use : A manually performed, visually interpreted Rapid Vertical Flow® (RVF®) immunoassay design to detect SARS-CoV-2, Influenza A and/or Influenza B viruses, the causative agents of COVID-19 and seasonal flu, respectively, in the human throat and/or nasal swab specimens.
Cat. No. 815311009648
Qty. 20 tests per box
Cat. No. 815311009624
Qty. 5 tests per box
This product is not yet approved by the FDA and there cannot be sold at this time in the USA.
REVEALCOVID-19® PLUS detects the presence of total antibodies against SARS-CoV-2, indicating a previous infection or post vaccination. The screening for antibodies is essential to keep track of a patient’s current antibody status to either determine the effectiveness of post vaccination or to be reminded to receive a booster dose.
Point-of-Care : ideally suited for fingerstick whole blood testing at the point of patient care in settings requiring a portable and all-in-one testing solution.
Cat. No. 815311006173
Qty. 20 tests per box
Cat. No. 815311006388
Qty. 5 tests per box
This product is not yet approved by the FDA and there cannot be sold at this time in the USA.
REVEALCOVID-19® NabY Anti-RBD Antibody Test is an antibody test to determine the effectiveness of a patient’s neutralizing antibodies. These antibodies play key role within the immune system to SARS-CoV-2prior to infecting the cells. A continuous positive REVEALCOVID-19® Nab-Y Anti-RBD Antibody provides the patient the peace of mind to be protected and allows a stress-free daily life.
Point-of-Care : ideally suited for fingerstick whole blood testing at the point of patient care in settings requiring a portable and all-in-one testing solution.
Cat. No. 815311007064
Qty. 20 tests per box
Qty. 20 tests per box
Cat. No. 815311007088
Qty. 5 tests per box
This product is not yet approved by the FDA and there cannot be sold at this time in the USA.
©2020 MedMira Inc. All Rights Reserved.